Bexson Biomedical is developing a subcutaneous delivery system for its BB106 non-opioid therapy, targeting acute pain management to provide an alternative to opioids. The company's formulation platform enhances the pharmacokinetics of existing drugs, enabling effective home health delivery and addressing the challenges of pain treatment without the risks associated with opioid use.
Funding
$12.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The opioid crisis demands effective, non-addictive alternatives for acute pain management. Current pain treatment options often carry significant risks, including dependency and adverse side effects, while effective home health delivery of pain medication remains a challenge.
Solution
Bexson Biomedical is developing BB106, a non-opioid therapy for acute pain management, delivered via a subcutaneous delivery system. Their formulation platform enhances the pharmacokinetics of existing small molecule drugs, enabling effective home health delivery. By optimizing pH, osmolality, and volume, the platform facilitates subcutaneous administration and improves drug absorption, addressing the challenges of pain treatment without the risks associated with opioid use. The company is also partnering to create a modular, pre-filled, and pre-sterilized subcutaneous pump for drug delivery.
Target Audience
The primary target audience includes patients requiring acute pain management and healthcare providers seeking non-opioid alternatives for pain relief.
Features
- BB106 non-opioid therapy for acute pain management
- Formulation platform that enhances subcutaneous delivery of small molecules
- Optimization of pH, osmolality, and volume for improved pharmacokinetics
- Modular, pre-filled, and pre-sterilized subcutaneous pump development
- Programmable drug delivery platform adaptable for various drugs
- Seven-valence salt formulation to potentiate subcutaneous delivery